Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?

2.50
Hdl Handle:
http://hdl.handle.net/10541/59273
Title:
Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Authors:
Bedard, Philippe L; Freedman, Orit C; Howell, Anthony ( 0000-0002-3879-5991 ) ; Clemons, Mark
Abstract:
Endocrine therapy is probably the most important systemic therapy for hormone receptor positive breast cancer. Hormonal manipulation was the first targeted treatment employed in breast cancer therapy even before the role of the estrogen (ER) and progesterone receptors (PR) had been elucidated. Unfortunately, a substantial proportion of patients, despite being ER and/or PR positive, are either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Signaling through complex growth factor receptor pathways, which activate the ER are emerging as important causes of endocrine resistance. Targeted therapies, such as signal transduction inhibitors (STIs), are being explored as agents to be able to potentially overcome this crosstalk and thus, resistance to hormone treatment. This article reviews the biology of the ER, the proposed mechanisms of endocrine resistance, and ongoing clinical trials with STIs in combination with hormonal manipulation as a means to overcome endocrine resistance.
Affiliation:
Division of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada.
Citation:
Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? 2008, 108 (3):307-17 Breast Cancer Res. Treat.
Journal:
Breast Cancer Research and Treatment
Issue Date:
Apr-2008
URI:
http://hdl.handle.net/10541/59273
DOI:
10.1007/s10549-007-9606-8
PubMed ID:
18351454
Type:
Article
Language:
en
ISSN:
0167-6806
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorBedard, Philippe L-
dc.contributor.authorFreedman, Orit C-
dc.contributor.authorHowell, Anthony-
dc.contributor.authorClemons, Mark-
dc.date.accessioned2009-04-02T16:14:35Z-
dc.date.available2009-04-02T16:14:35Z-
dc.date.issued2008-04-
dc.identifier.citationOvercoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? 2008, 108 (3):307-17 Breast Cancer Res. Treat.en
dc.identifier.issn0167-6806-
dc.identifier.pmid18351454-
dc.identifier.doi10.1007/s10549-007-9606-8-
dc.identifier.urihttp://hdl.handle.net/10541/59273-
dc.description.abstractEndocrine therapy is probably the most important systemic therapy for hormone receptor positive breast cancer. Hormonal manipulation was the first targeted treatment employed in breast cancer therapy even before the role of the estrogen (ER) and progesterone receptors (PR) had been elucidated. Unfortunately, a substantial proportion of patients, despite being ER and/or PR positive, are either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Signaling through complex growth factor receptor pathways, which activate the ER are emerging as important causes of endocrine resistance. Targeted therapies, such as signal transduction inhibitors (STIs), are being explored as agents to be able to potentially overcome this crosstalk and thus, resistance to hormone treatment. This article reviews the biology of the ER, the proposed mechanisms of endocrine resistance, and ongoing clinical trials with STIs in combination with hormonal manipulation as a means to overcome endocrine resistance.en
dc.language.isoenen
dc.subjectEndocrine Resistanceen
dc.subjectEstrogen Receptoren
dc.subjectBreast Canceren
dc.subjectEndocrine Therapyen
dc.subjectHormone-Dependent Canceren
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeoplasms, Hormone-Dependent-
dc.subject.meshReceptors, Estrogen-
dc.subject.meshSignal Transduction-
dc.titleOvercoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada.en
dc.identifier.journalBreast Cancer Research and Treatmenten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.